JP2022504722A - 造血幹細胞および造血前駆細胞の増殖システム - Google Patents

造血幹細胞および造血前駆細胞の増殖システム Download PDF

Info

Publication number
JP2022504722A
JP2022504722A JP2021519858A JP2021519858A JP2022504722A JP 2022504722 A JP2022504722 A JP 2022504722A JP 2021519858 A JP2021519858 A JP 2021519858A JP 2021519858 A JP2021519858 A JP 2021519858A JP 2022504722 A JP2022504722 A JP 2022504722A
Authority
JP
Japan
Prior art keywords
medium
acid
inhibitor
salt
hsc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021519858A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022504722A5 (https=
Inventor
ジャネット セイ
アビゲイル ベッカー
ナヴジョット カウル
モハン ヴェムリ
Original Assignee
ライフ テクノロジーズ コーポレーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ライフ テクノロジーズ コーポレーション filed Critical ライフ テクノロジーズ コーポレーション
Publication of JP2022504722A publication Critical patent/JP2022504722A/ja
Publication of JP2022504722A5 publication Critical patent/JP2022504722A5/ja
Priority to JP2024099903A priority Critical patent/JP2024137954A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0647—Haematopoietic stem cells; Uncommitted or multipotent progenitors
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/0018—Culture media for cell or tissue culture
    • C12N5/0037—Serum-free medium, which may still contain naturally-sourced components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/05—Inorganic components
    • C12N2500/10—Metals; Metal chelators
    • C12N2500/20—Transition metals
    • C12N2500/24—Iron; Fe chelators; Transferrin
    • C12N2500/25—Insulin-transferrin; Insulin-transferrin-selenium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2500/00—Specific components of cell culture medium
    • C12N2500/99—Serum-free medium
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/065—Modulators of histone acetylation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/145—Thrombopoietin [TPO]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2303—Interleukin-3 (IL-3)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2306—Interleukin-6 (IL-6)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/70—Enzymes
    • C12N2501/72—Transferases [EC 2.]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Developmental Biology & Embryology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2021519858A 2018-10-12 2019-10-14 造血幹細胞および造血前駆細胞の増殖システム Pending JP2022504722A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024099903A JP2024137954A (ja) 2018-10-12 2024-06-20 造血幹細胞および造血前駆細胞の増殖システム

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862745208P 2018-10-12 2018-10-12
US62/745,208 2018-10-12
US201962854250P 2019-05-29 2019-05-29
US62/854,250 2019-05-29
PCT/US2019/056145 WO2020077343A1 (en) 2018-10-12 2019-10-14 Hematopoietic stem and progenitor cell expansion system

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024099903A Division JP2024137954A (ja) 2018-10-12 2024-06-20 造血幹細胞および造血前駆細胞の増殖システム

Publications (2)

Publication Number Publication Date
JP2022504722A true JP2022504722A (ja) 2022-01-13
JP2022504722A5 JP2022504722A5 (https=) 2022-10-20

Family

ID=68426859

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021519858A Pending JP2022504722A (ja) 2018-10-12 2019-10-14 造血幹細胞および造血前駆細胞の増殖システム
JP2024099903A Pending JP2024137954A (ja) 2018-10-12 2024-06-20 造血幹細胞および造血前駆細胞の増殖システム

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024099903A Pending JP2024137954A (ja) 2018-10-12 2024-06-20 造血幹細胞および造血前駆細胞の増殖システム

Country Status (6)

Country Link
US (1) US20210386787A1 (https=)
EP (1) EP3863648A1 (https=)
JP (2) JP2022504722A (https=)
KR (1) KR20210076048A (https=)
CN (1) CN112805015A (https=)
WO (1) WO2020077343A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2024539519A (ja) * 2021-10-20 2024-10-28 エクシール， インク． 非ヒト霊長類の個別化されたゲノムアセンブリ及び人工多能性幹細胞株を前臨床評価に使用するための組成物及び方法
CN114891749B (zh) * 2022-07-13 2022-12-02 杭州艾名医学科技有限公司 一种胰腺癌类器官的培养基及胰腺癌类器官的培养方法
CN115975929A (zh) * 2022-08-18 2023-04-18 南通大学 Kat2a抑制剂在治疗脊髓及坐骨神经损伤中的应用
CN115644066B (zh) * 2022-12-02 2024-01-16 福建农林大学 利用外源多胺提高龙眼胚性愈伤组织生长量和类黄酮含量的方法
LU507930B1 (en) * 2024-08-05 2026-02-05 Luxembourg Institute Of Science And Tech Serum-free culture medium for the culture of human monocytic cells and method using the same

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009509911A (ja) * 2005-05-05 2009-03-12 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ リンパ造血組織を定着させるためのｍａｐｃまたはそれらの子孫の使用
WO2011158806A1 (ja) * 2010-06-14 2011-12-22 日産化学工業株式会社 造血幹細胞の製造方法
JP2013528397A (ja) * 2010-06-15 2013-07-11 セルラー ダイナミクス インターナショナル， インコーポレイテッド 少量の末梢血からの人工多能性幹細胞の作製
JP2014530012A (ja) * 2011-09-30 2014-11-17 ブルーバードバイオ， インコーポレイテッド 改善されたウイルスによる形質導入のための化合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1170008A1 (en) * 2000-07-07 2002-01-09 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus Valproic acid and derivatives thereof as histone deacetylase inhibitors
KR20110019727A (ko) * 2008-04-07 2011-02-28 뉴포텐셜, 인크. Ｒｎａ 간섭을 통한 다능 유전자의 유도에 의한 세포 재프로그래밍
JP5694946B2 (ja) * 2008-12-03 2015-04-01 インターナショナル ステム セル コーポレイション 幹細胞から分化細胞を得る方法
WO2010108126A2 (en) * 2009-03-19 2010-09-23 Fate Therapeutics, Inc. Reprogramming compositions and methods of using the same
WO2013086029A1 (en) * 2011-12-05 2013-06-13 Primorigen Biosciences Inc. Compositions and methods for differentiating pluripotent stem cells into primitive blood cells and uses thereof
EP2982745A1 (en) * 2014-08-06 2016-02-10 Johann Wolfgang Goethe-Universität, Frankfurt am Main Method for expanding immune cells
US10669528B2 (en) * 2015-06-25 2020-06-02 Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion, enrichment, and maintenance
EP4049665B1 (en) * 2016-03-15 2025-03-12 The Children's Medical Center Corporation Methods and compositions relating to hematopoietic stem cell expansion
WO2018160028A1 (ko) * 2017-03-02 2018-09-07 주식회사 셀라토즈테라퓨틱스 신경세포 분화용 배지 조성물 및 상기 배지 조성물을 이용한 체세포로부터 신경세포로의 분화 방법

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009509911A (ja) * 2005-05-05 2009-03-12 リージェンツ オブ ザ ユニバーシティ オブ ミネソタ リンパ造血組織を定着させるためのｍａｐｃまたはそれらの子孫の使用
WO2011158806A1 (ja) * 2010-06-14 2011-12-22 日産化学工業株式会社 造血幹細胞の製造方法
JP2013528397A (ja) * 2010-06-15 2013-07-11 セルラー ダイナミクス インターナショナル， インコーポレイテッド 少量の末梢血からの人工多能性幹細胞の作製
JP2014530012A (ja) * 2011-09-30 2014-11-17 ブルーバードバイオ， インコーポレイテッド 改善されたウイルスによる形質導入のための化合物

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BLOOD CANCER JOURNAL, vol. 1, JPN6024006010, 2011, pages 36, ISSN: 0005264744 *
CRJ LETTERS, vol. 20, JPN6024006009, 2018, pages 1 - 10, ISSN: 0005264743 *
INT. J. HEMATOL., vol. 103, JPN6023033699, 2016, pages 519 - 529, ISSN: 0005405323 *
TRANSPLANTATION DIRECT, vol. 6, JPN6024006011, 2020, pages 579, ISSN: 0005264745 *

Also Published As

Publication number Publication date
KR20210076048A (ko) 2021-06-23
EP3863648A1 (en) 2021-08-18
CN112805015A (zh) 2021-05-14
JP2024137954A (ja) 2024-10-07
US20210386787A1 (en) 2021-12-16
WO2020077343A1 (en) 2020-04-16

Similar Documents

Publication Publication Date Title
JP2022504722A (ja) 造血幹細胞および造血前駆細胞の増殖システム
US20250215396A1 (en) Compositions and methods for immune cell modulation in adoptive immunotherapies
JP7410899B2 (ja) 間葉系幹細胞の細胞培養法
JP2024001145A (ja) 養子免疫療法における免疫細胞調節のための組成物および方法
EP2565263A1 (en) Culture medium additive and uses thereof
JP6882161B2 (ja) 改善された幹細胞組成物
BR112014020119A2 (pt) cultura de células-tronco mesenquimais
CN107043747A (zh) 一种人脐带间充质干细胞无血清培养基
KR102861022B1 (ko) 조혈 이식체의 개선 방법
JP2017526619A (ja) 免疫疾患の治療
US20200140817A1 (en) Hematopoietic stem cell expansion method
US20020159984A1 (en) Cultivation of cells for long term engraftment
CN113557296A (zh) 造血干细胞的扩增
CN104017770B (zh) 一种利用糖脂制备cik细胞的方法
JP2004135672A (ja) 動物細胞又は組織を培養するための、ポリエチレングリコールを含んで成る組成物
Suzuki et al. Improving the viability of tissue‐resident stem cells using an organ‐preservation solution
US20210379112A1 (en) Stem cell therapy
EP4733383A1 (en) Culture medium and blood cell clone, and method for producing same
AU2023201552B2 (en) Compositions and methods for immune cell modulation in adoptive immunotherapies
Gogusev et al. DOR‐1, A novel CD10+ stromal cell line derived from progressive Langerhans cell histiocytosis of bone
Choe et al. Allogeneic serum improves the expansion and maintenance of canine mesenchymal stem cells
US20090169523A1 (en) Hsc self-renewal
JP2023035731A (ja) 造血幹細胞培養組成物
Lim et al. Cord blood expansion with selective depletion of CD52 positive cells using Campath-1H: Increased CD34+ cells and megakaryocytic progenitors
Nivison-Smith et al. Measurement of mortality in long-term hemopoietic stem cell transplant survivors

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221011

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221011

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230817

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20231116

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240117

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240220

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240620

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20240813

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20240906